BusinessNeuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive DisorderBy Nasdaq OMXMay 17, 2017, 8:06 PM UTC
BusinessNeuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive DisorderBy Nasdaq OMXMay 17, 2017, 8:06 PM UTC
BusinessNeuralstem Announces Publication of NSI-189 Preclinical Data in Journal of Cellular PhysiologyBy Nasdaq OMXFeb 28, 2017, 12:03 PM UTC
BusinessNeuralstem Announces Issuance of U.S. Patent Covering NSI-189By Nasdaq OMXFeb 22, 2017, 12:03 PM UTC
BusinessNeuralstem Announces the Closing of $20 Million Strategic Investment from Tianjin Pharmaceutical Group International Holdings Co., LTD.By Nasdaq OMXDec 12, 2016, 12:38 PM UTC
